1. Scrip
  2. >>Business
  3. >>Strategy

Gilead Shines Some Light On Its Inflammation Ambitions

Part Of Ongoing Diversification Strategy

 
• By Mandy Jackson

CEO Daniel O’Day and EVP-research Flavius Martin highlighted Gilead’s inflammation R&D and dealmaking focus at the recent J.P. Morgan meeting.

Gilead announced a new deal and reworked an old deal in inflammation already this year (Shutterstock)

Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do to create a comparable pipeline in inflammation. CEO Daniel O’Day and other executives shed some light on the plans to expand in inflammation during the J.P. Morgan Healthcare Conference, just days after buying inflammation assets from LEO Pharma.

Key Takeaways
  • Gilead is diversifying its portfolio over the long term, with inflammation as an important but earlier-stage area of growth, through both internal R&D and external business development.

On 12 January, Gilead announced it will pay $250m up front for LEO’s preclinical oral small...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

More from Conferences

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.